Cardionomic STOP-ADHF Study

NCT ID: NCT04814134

Last Updated: 2024-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-12

Study Completion Date

2024-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

STOP-ADHF Study: An evaluation of the safety and performance of the Cardionomic Cardiac Pulmonary Nerve Stimulation (CPNS) system in patients with acute decompensated heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The STOP-ADHF is a prospective, two-arm, multi-center study to evaluate the safety and performance of the CPNS System in patients with acute decompensated heart failure (ADHF).

The CPNS System is a neuromodulation system, intended to provide acute (≤5 days) endovascular stimulation of the cardiac autonomic nerves in the right pulmonary artery. The system consists of a temporary neuromodulation stimulator catheter and a stimulator.

Approximately 90 patients will be enrolled in the study and will be followed up through 6-months post-discharge from the hospital. Patients enrolled in the treatment group will receive CPNS therapy and followed closely in an intensive care unit setting. Patients enrolled in the control arm in will receive standard treatment for their heart failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Decompensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Subjects will be enrolled in CPNS treatment arm or to the control arm. Treatment with CPNS system includes endovascular stimulation of the cardiac autonomic nerves in addition to standard of care. Subjects in the control arm will receive the available standard treatment.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPNS Therapy

Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care

Group Type EXPERIMENTAL

CPNS Therapy

Intervention Type DEVICE

Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care

Standard of care

Intervention Type OTHER

Available standard treatment

Standard of Care

Available standard treatment

Group Type OTHER

Standard of care

Intervention Type OTHER

Available standard treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPNS Therapy

Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care

Intervention Type DEVICE

Standard of care

Available standard treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted to hospital with a principal diagnosis of ADHF
* BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL
* LVEF ≤ 50%
* At least one sign or symptom of fluid overload despite the administration of IV furosemide (or equivalent) (at least 40 mg or equivalent)

Exclusion Criteria

* Received a high dose inotrope or Levosimendan during current hospitalization or treatment with a low dose inotriope within 24 hours before enrollment
* Requires mechanical support
* Cardiogenic shock or impending cardiogenic shock
* Systolic blood pressure \< 80mmHg or \> 140mmHg
* Symptomatic hypotension
* eGFR \< 25 mL/min/1.732
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardionomic Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Vincent Hospital

Indianapolis, Indiana, United States

Site Status

Summa Health

Akron, Ohio, United States

Site Status

The Christ Hospital

Cincinnati, Ohio, United States

Site Status

University Hospitals

Cleveland, Ohio, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

Oklahoma Heart Hospital South

Oklahoma City, Oklahoma, United States

Site Status

TriStar Centennial Medical Center

Nashville, Tennessee, United States

Site Status

Medical City Fort Worth

Fort Worth, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

OLV Ziekenhuis

Aalst, , Belgium

Site Status

AZ Sint-Jan Brugge

Bruges, , Belgium

Site Status

Antwerp University Hospital

Edegem, , Belgium

Site Status

University Medical Center Groningen

Groningen, , Netherlands

Site Status

St. Antonius Ziekenhuis

Nieuwegein, , Netherlands

Site Status

Punta Pacifica

Panama City, , Panama

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Netherlands Panama

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLN-1051-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epiphrenic III Pilot Trial
NCT01837771 UNKNOWN NA
CARE-HF Long Term Follow-up
NCT00318357 COMPLETED